0 2 4 6 8 10 0 4 8 12 16 20 24 28 32 36 40 44 48 Zenkuda Sham GLOW2 – Visual acuity and retinal anatomy were stable over time -50 0 50 0 4 8 12 16 20 24 28 32 36 40 44 48 ETDRS Letters μm Week BCVA: best-corrected visual acuity; ETDRS: early treatment diabetic retinopathy study; CST: central subfield thickness; μm: microns Sham (n=125); Zenkuda (n=130); Results are based on a MMRM model including the change from baseline value as the dependent variable. Patients that developed sight-threatening complications in either arm were treated with open-label Zenkuda and all subsequent data was censored. Adjusted Mean Change in BCVA from Baseline Data censored after diagnosis of sight-threatening complications Adjusted Mean Change in OCT CST from Baseline Data censored after diagnosis of sight-threatening complications 82.0 (20/25+2) 82.5 (20/25+2) Week 48 Observed BCVA 288.3 263.8 Week 48 Observed OCT CST Figure 9